Video

Dr. Smith on Ongoing Research in Relapsed/Refractory MCL

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, interim chief, Section of Hematology/Oncology, director, Lymphoma Program, University of Chicago Medicine, discusses ongoing research in relapsed/refractory mantle cell lymphoma (MCL).

Despite the introduction of BTK inhibitors, relapsed/refractory MCL remains incurable and is associated with poor survival, says Smith.

CAR T-cell therapy is an area of active research that appears promising, says Smith. Although the data sets are relatively small, CAR T-cell therapy could offer a different way of treating patients with MCL compared with traditional chemotherapy. The modality could also lead to better disease control, explains Smith.

Additionally, combinations of BCL-2 inhibitors with BTK inhibitors are also being investigated in the relapsed/refractory setting, concludes Smith.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma